Lazuvapagon
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Lazuvapagon
- DrugBank Accession Number
- DB19046
- Background
Lazuvapagon is under investigation in clinical trial NCT03116191 (Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 460.578
Monoisotopic: 460.247440906 - Chemical Formula
- C27H32N4O3
- Synonyms
- (4s)-n-((2s)-1-hydroxypropan-2-yl)-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-2,3,4,5-tetrahydro-1h-1-benzazepine-4-carboxamide
- 1h-1-benzazepine-4-carboxamide, 2,3,4,5-tetrahydro-n-((1s)-2-hydroxy-1-methylethyl)-4-methyl-1-(2-methyl-4-(3-methyl-1h-pyrazol-1-yl)benzoyl)-, (4s)-
- External IDs
- KRP-N118
- SK-1404
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- CK6VS66Q6X
- CAS number
- 2379889-71-9
- InChI Key
- BKHSWGKGWGWMSM-CCLHPLFOSA-N
- InChI
- InChI=1S/C27H32N4O3/c1-18-15-22(31-13-11-19(2)29-31)9-10-23(18)25(33)30-14-12-27(4,26(34)28-20(3)17-32)16-21-7-5-6-8-24(21)30/h5-11,13,15,20,32H,12,14,16-17H2,1-4H3,(H,28,34)/t20-,27-/m0/s1
- IUPAC Name
- SMILES
- C[C@@H](CO)NC(=O)[C@]1(C)CCN(C(=O)C2=CC=C(C=C2C)N2C=CC(C)=N2)C2=CC=CC=C2C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 88297953
- ChEMBL
- CHEMBL4802162
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data2 Completed Treatment Nocturia Due to Nocturnal Polyuria 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 02, 2024 21:01 / Updated at July 03, 2024 00:11